# Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

> **NCT07091695** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 100 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Nivolumab + relatlimab
- **BIOLOGICAL:** Nivolumab + ipilimumab

## Key facts

- **NCT ID:** NCT07091695
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-11
- **Primary completion:** 2025-11-06
- **Final completion:** 2025-11-06
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07091695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07091695, "Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07091695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*